PIII earnings analysis
What we found in PIII's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
P3 delivered Q2 revenue of $386.381 million and diluted EPS of $(0.63), beating consensus estimates of $377.8 million and $(1.90), while adjusted EBITDA improved to $54.4 million from a $(17.1) million loss in the prior-year quarter. However, EPS declined from $0.32 in Q1 2026, first-half operating cash use was $89.4 million, and the filing states that substantial doubt exists about the company’s ability to continue as a going concern. The $252.5 million debt exchange and additional preferred financing improve near-term capital access but create approximately $308.4 million of senior preferred claims accruing dividends at 13.5% to 19.5%, making the outlook mixed.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat and Year-over-Year Growth
- Q2 revenue was $386.381 million, up from $356 million in Q2 2025, an increase of $30.381 million or 8.5%. Revenue exceeded the $377.8 million consensus estimate by $8.581 million, or 2.3%.
- EPS Materially Better Year Over Year
- Diluted EPS was $(0.63), improving by $5.60 from $(6.23) in Q2 2025, but declining by $0.95 from $0.32 in Q1 2026. EPS exceeded the $(1.90) consensus estimate by $1.27.
- Sharp Adjusted EBITDA Improvement
- Adjusted EBITDA was $54.4 million versus an adjusted EBITDA loss of $17.1 million in the prior-year quarter, a year-over-year improvement of $71.5 million.
- Debt Exchange Reduced Promissory Notes
- The company exchanged approximately $252.5 million of outstanding promissory notes, including principal, accrued interest and back-end fees, for non-convertible preferred stock on April 27, 2026.
- Additional Preferred Capital Raised
- The company sold $51.3 million of Series D preferred-stock units as of June 30, 2026 and sold an additional $16.0 million on July 1, 2026, providing additional capital under the $70.0 million purchase agreement.
- Disclosure Controls Remained Effective
- Management reported that disclosure controls were effective as of June 30, 2026 and that there were no changes in internal control over financial reporting during the quarter that materially affected, or were reasonably likely to materially affect, controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large Senior Preferred Dividend Burden
- Cumulative preferred dividends accrue at rates of 13.5% to 19.5% on approximately $308.4 million of preferred-stock stated value. For the three months ended June 30, 2026, $9.6 million of preferred dividends converted $7.4 million of net income attributable to the controlling interest into a $2.1 million net loss attributable to Class A common stockholders.
- Going-Concern and Liquidity Risk
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern. The cumulative preferred-stock obligation adds a further claim on limited cash resources, with preferred-stock stated value of approximately $308.4 million and dividend rates as high as 19.5%.
- Ongoing DOJ Investigation
- The company received a civil investigative demand from the DOJ in June 2024 under the False Claims Act concerning insurance-agent and broker arrangements, including remuneration paid to Medicare Advantage brokers. The filing states that no assurance can be given regarding the timing or outcome of the investigation.
- Concentrated CPF Control and Conflicts
- All outstanding preferred stock is held by affiliates of Chicago Pacific Founders, which also holds approximately 40% of the company’s outstanding common stock and has rights to designate an additional independent board member plus information and protective rights.
- Warrant Dilution and Resale Pressure
- The Series D preferred-stock issuances included warrants to purchase Class A common stock. Exercise of those warrants would dilute existing common stockholders, and the company agreed to facilitate resale registration of the underlying shares, which could create additional selling pressure.
- Senior Claims Constrain Capital Flexibility
- The preferred stock ranks senior to all common stock and carries a $100.00-per-share liquidation preference plus accumulated and unpaid dividends. As of June 30, 2026, the company had sold $51.3 million of Series D units, with $18.7 million remaining available under the purchase agreement.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.63
What they said about what is next.
Full-year 2026 revenue outlook was $1.5 billion-$1.6 billion. Management raised full-year 2026 adjusted EBITDA guidance to $80 million-$110 million; the filing/release did not disclose numerical EPS guidance.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- P3 Health Partners reported Q4 2026 results showing total revenue of $384.8 million, exceeding estimates by 7.6%. Despite this revenue increase, the company faced significant losses, posting an EPS of -23.02, reflecting…
- 10-K · March 26, 2026
- P3 Health Partners presents a physician-led value-based care strategy (the “P3 Care Model”) focused on Medicare Advantage and capitated PMPM arrangements, supported by 2,400 contracted PCPs and a physician retention…
- 10-Q · November 14, 2025
- P3 Health Partners reported Q3 2025 operating revenue of $345,253,000 and a net loss of $69,461,000 (basic EPS $(9.67)). Operating loss narrowed to $44,223,000 from $106,990,000 in Q3 2024, but the company remains…
- 10-Q · May 15, 2025
- P3 Health Partners reported Q1 2025 revenue of $373.225 million, down from $388.488 million in Q1 2024, with a GAAP net loss per share of $(6.28). Operating loss narrowed to $(38.088) million (−10.2% of revenue) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PIII makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever